Biohit GastroPanel enters into global market by co-operation with Randox

GastroPanel- availability expands substantially when Randox started the global sales of its CE-labelled  MULTIPLEX GASROINTESTINAL PANEL-test based on the Biohit license (1). Randox is a British health technology enterprise operating on global market, with the annual turnover of around 730 million euro in 2021.

GastroPanel is a diagnostic blood test developed by Biohit Oyj, detecting Helicobacter infection in the stomach, atrophic gastritis (stomach mucosal a trophy) as well as the level of gastric acid output, thus disclosing the potential risks associated with these conditions, e.g.  gastric- and esophageal cancer as well as  deficiency of vitamin-B12 and iron (2). GastroPanel does not replace endoscopic examination (gastroscopy), but as a screening- and diagnostic blood test, GastroPanel has several advantages as compared with invasive gastroscopy which is felt uncomfortable by most patients.

Quick, easy and cost-effective GastroPanel saves resources of an overloaded health care while helping in a timely referral for gastroscopy of those patients who truly need it (3). Stomach mucosal atrophy and eventually resulting gastric cancer can be diagnosed only by gastroscopy. Far too often, this happens too late, when the patient already presents with cancer-related alarming symptoms, at which stage the disease outlook is poor.  In Finland, 1016 new patients were diagnosed with gastric- and esophageal cancer in 2021, and 785 patients died of these cancers. Accordingly, clinical examination of the upper abdominal symptoms as well as screening of asymptomatic subjects at risk is of prime importance for primary prevention and early diagnosis (4). Gastric cancer is the fifth most common cancer worldwide. In Europe, it is ranking fourth among the most fatal cancers.

The multiplex version of the GastroPanel test, launched by Randox based on the Biohit license, is an excellent addition to the existing test platforms and undoubtedly increases the visibility and use of GastroPanel worldwide. Co-operation with Randox is a strong signal of the major potential of Biohit innovations.

The Biochip Array Technology (BAT) developed by Randox permits a simultaneous measurement of the three GastroPanel biomarkers (pepsinogen I, pepsinogen II and gastrin-17) in a single blood sample. When  Helicobacter pylori–test is being made from the same sample using the  same test platform, testing is extremely rapid and cost-effective.

Biohit welcomes the Randox multiplex GastroPanel into global market. 

Additional information: 
[email protected]
www.biohithealthcare.com

 Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

References  

1.https://www.randox.com/gastrointestinal-biochip-arrays/?highlight=gastropanel

2.https://www.biohithealthcare.com/additional-information

3.https://www.biohithealthcare.com /News/Reading material: GastroPanel innovation

4.https://www.biohithealthcare.com /Investors/Stock Exchange Releases: 2022-08-09T10:00:00Z – Dyspeptic symptoms need early attention- domestic innovations GastroPanel®, ColonView-FIT® and Acetium® will help